Skip to main content
. Author manuscript; available in PMC: 2021 Mar 11.
Published in final edited form as: J Urol. 2016 Sep 6;197(3 Pt 1):640–646. doi: 10.1016/j.juro.2016.08.109

Table 1.

Active surveillance criteria definitions

AS Criteria Clinical Stage PSA (ng/ml) Gleason Grade Total Pos Cores % Single Core Pos PSAD (ng/ml/cc)
NIH risk:
 Low T2a or less 20 or Less 3 + 3 or Less
 Expanded T2a or less 20 or Less 3 + 4 or Less 33% or Less
Epstein T1c or less 3 + 3 or Less 2 or Less 50% or Less 0.15 or Less
Toronto 10 or Less 3 + 3 or Less
PRIAS T2a or less 10 or Less 3 + 3 or Less 2 or Less 0.2 or Less
Royal Marsden T2a or less 15 or Less 3 + 4 or Less 50% or Less